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Objectives . The aim of this study was to retrospectively evalu .
ate the sensitivity of noninvasive surveillance
(physical examina-
tionn, echocardiography) of rejection In accurately predicting
histologically documented rejection episodes
. Additionally, the
usefulness of routine scheduled biopsy and its safety in pediatric
patients was explored.
Background.
Endomyocardial biopsy has been utilized as the
standard for rejection surveillance
after heart transplantation in
adults, but its role in documenting clinically suspected rejection
and In routine surveillance of pediatric patients has not been
agreed upon
.
Methods. Heart transplantation was performed in 14 neonates
and 21 children. The immunosuppressive regimen consisted of
cyclosporine, azathioprine and prednisone. All patients under-
went routine noninvasive rejection surveillance that included
clinical examination and echocardiography. In the neonates,
biopsy was performed quarterly beginning 6 months after trans-
plantation, after cessation of prednisone therapy. In the children,
biopsy was performed 15 times in the 1st year . A minimum of five
Despite improved immunosuppression, the early and accu-
rate diagnosis of acute rejection after heart transplantation
remains a challenge (1-7) . Previous reports (8-12) demon-
strating the utility of endomyocardial biopsy for reliably
detecting cellular rejection have established the biopsy as
the standard for rejection surveillance after heart transplan-
tation in adults . This experience, dating back to 1972, comes
from the Stanford University Heart Transplant Program,
which began invasive rejection surveillance using the biop-
tome designed by Caves et al . (13), with interpretation of
tissue by Billingham (8) . Endomyocardial biopsy has not
been widely utilized in infants and young children for many
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biopsy samples
were
interpreted using the Working Formulation
for Heart Transplant Rejection .
Results, In the
neonates, 37 biopsies were performed. Evidence
of rejection was present in only three biopsy samples obtained
during eight episodes (38%) of clinically suspected rejection. In 29
biopsies performed when rejection was not clinically suspected,
each biopsy was free of cellular infiltrate. In the children, 291
biopsies were performed. Evidence of rejection was present in
only seven biopsies (410) from 17 episodes ofclinically suspected
rejection . Cellular rejection was discovered during routine rejec-
tion surveillance biopsies in asymptomatic patients in 23 (8.4%) of
274 biopsies .
Conclusions. In neonates with clinically suspected rejection,
endomyocardial biopsy identified which patients did not require
rejection therapy . Endomyocardial biopsy surveillance did not
detect any unsuspected cases of rejection. In children, noninvasive
rejection surveillance was less reliable even in asymptornatic
patients, suggesting that
periodic
eadomyocardial biopsy should
be utilized .
(I Am Coll Cardiol 1994,23 :766-71)
reasons including the proposed need for general anesthesia,
risk of ventricular perforation and thrombosis of access
vessels and poor myocardial sampling yield (14,15) . In
addition, some investigators (14) believe that rejection can
be detected noninvasively without need for biopsy sampling .
The objectives of this study were 1) to retrospectively
evaluate the sensitivity of noninvasive rejection surveillance
(physical examination and echocardiography) in accurately
predicting histologically documented rejection episodes ;
2) to evaluate the usefulness of routine scheduled biopsies ;
and 3) to evaluate the safety of endomyocardial biopsy in
pediatric patients .
Methods
Patients. Between May 1986 and November 1991 we
performed orthotopic heart transplantation in 35 patients .
Group I consisted of 14 neonates ; the diagnosis was hypo-
plastic left heart syndrome in 13 and aortic stenosis with .
severe endocardial fibroelastosis in 1 . The mean age at
transplantation was 19 days (range 2 to 49). Group II
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consisted of 21 children ; the diagnosis was cardiomyopathy
in 16, postoperative congenital heart disease with refractory
ventricular failure in 4 and chronic rejection requiring a
second heart transplantation in 1 . The mean age at trans-
plantation was 7 years (range I to 17) .
Immunosuppressive regimen. The posttransplantation
immunosuppressive regimen was based on triple therapy
with cyclosporine, azathioprine, and prednisone . Cyclospo-
rine was administered orally two or three times a day to
maintain trough whole blood concentration measured by
high pressure liquid chromatography >150 ng/ml in the
neonatal patients and 000 ng/ml in children . Azathioprine
treatment was started at 2 mg/kg body weight per day and
titrated to a white blood cell count of 5,000/mm 3. Prednisone
dosage was begun at 1 mg/kg per day for the I a 2 weeks and
was gradually decreased to 0 .2 mg/kg per day by 8 weeks
after transplantation. In Group 1, efforts were made to
discontinue prednisone at 6 months as guided by endomyo-
cardial biopsy findings .
Acute cellular rejection (grade >2 International Society
of Heart Transplantation) (16) was treated with 16 nylg
intravenous methylprednisolone daily for 3 days . OKT3
(Ortho) was administered at 2,5 to 10 mg/dose for 7 to 14
days for the management of rejection refractory to steroid
pulse therapy or associated with ventricular dysfunction .
Rejection surveillance . Noninvasive rejection surveil-
lance . Clinical assessment included nursing and parental
accounts of heart rate and of charge% in the patient's activity
or appetite, or both . Reduced activity or appetite prompted
further investigation . Atrial or ventricular ectopic activity or
tachycardia at rest, defined as an increase in heart rate of 15
to 20 beats/min above the normal baseline rate at rest, was
considered suspicious for rejection and an echocardiogram
was performed .
Routine echocardiographic studies in all patients were
performed twice weekly in the 1st month, weekly in the 2nd
month and monthly thereafter through the end of the I st year
after transplantation . An echocardiogram was also employed
whenever rejection was clinically suspected . Echocardio-
graphy measured left ventricular dimensions, posterior wall
thickness and shortening fraction . Acute left ventricular
end-diastolic dimension increases of 20%, left ventricular
posterior wall increases of 20% and left ventricular shorten-
ing fraction decreases of 20% were deemed significant . The
presence of a pericardial effusion or new valvular regurgita-
tion provided supportive data for rejection .
Invasive rejection surveillance . In Group I
routine quar-
terly biopsies were performed beginning 6 months after
transplantation and continuing until 18 months after trans-
plantation, and then with each anr;ual comprehensive cath-
eterization. During the 1st 6 months after transplantation,
biopsy also was performed when clinically suspected rejec-
tion episodes did not resolve after one course of antirejection
therapy. In Group II, routine biopsies were performed
weekly for the 1st month, biweekly in the 2nd and 3rd
months and monthly until the 9th month . Biopsies were
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performed quarterly thereafter until 18 months after trans-
plantation and then with each comprehensive annual cathe-
terization . Biopsy was also performed if rejek - tion was clin-
ically suspected
. If any biopsy sample demonstrated
rejection, serial biopsy samples were evaluated until the
episode clearly resolved .
Biopsy technique . All biopsies were performed on an
outpatient basis after hospital discharge after transplanta-
tion
. In patients <5 years of age, light sedation was estab-
lished with short-acting intravenous fentanyl/droperidol or
midazolam, and local anesthesia was provided with lido-
caine . In patients >5 years of age, no sedatives were
administered, but adequate local anesthesia was obtained
with lidocaine . All patients received heparin (50 U/kg) .
After venous access and measurement of right heart
pressures and cardiac index, a 6F Mullins transseptal sheath
(USCI) was advanced over a balloon wedge catheter to the
right ventricular apex and the pressure transduced through a
side-arm sheath . A 5.617 bioptome (Mansfield Byceps) with
1 .8-mm jaws was utilized to obtain five to eight undomyo-
tadial biopsy samples from different sites along the right
ventricular septum and apex .
Safety evaluation. An echocardiogram was performed
after the biopsy to exclude hemopericardium, and fluoros-
copy of the chest was done to rule out pneumothorax after a
jugular approach . Patients were hen sent to the outpatient
day hospital for 6 h of observation and discharged if the
biopsy sample showed no evidence of rejection .
Evaluation of biopsy samples . The tissue analysis of the
five to eight endomyocardial biopsy samples consisted of a
4-h short cycle processing technique . Hernatoxylin/phlox ine/
saffarin stain for light microscopy was employed because of
its usefulness in identifying old biopsy sites and myocyte
damage associated with rejection. Eight histologic sections
were carefully reviewed and graded according to the Work-
ing Formulation for Heart Transplant Rejection (16) .
Statistical methods . To compare clinical surveillance with
biopsy, clinically suspected rejection episodes (as defined
earlier) were evaluated by biopsy . For these comparisons,
the biopsy results were defined as the reference standard and
as the unit of analysis (8,11,16) . A proportion estimate was
computed for the proportion of clinically suspected zowdes
confirmed by biopsy . To evaluate the utility of periodic
surveillance by biopsy, both the proporticri of rejection
episodes detected in this manner and the proportion of times
that periodic surveillance revealed evidence of rejection
were computed. Ninety-five percent confidence intervals for
each proportion estimate were computed, using the methods
of Clopper and Pearson (17) . Similar one-sided intervals
were computed for safety of biopsy .
Results
Transplantation outcome
. In Group 1, 9 of 14 neonates
had survived at a mean follow-up time of 25 months (range 9
to 36). There were five deaths
: three from infection and two
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sudden deaths from acute cellular rejection at 35 days and
375 days, respectively, after transplantation . (The latter
death occurred before initiation of the protocol .)
In Group II, 16 of 21 children had survived at a mean
follow-up time of 21 .5 months (range I to 42) . There were
five deaths: two from donor graft failure, one from acute
cellular rejection 18 days after repeat transplantation (after 2
negative biopsies), one from posttransplantation lymphopro-
liferative disorder and one from sepsis .
Rejection numlHance . Group 1. Twelve episodes of re-
jection occurring in eight neonatal transplant recipients were
clinically suspected and treated in the 1st 6 months after
transplantation before invasive surveillance began . Clinical
and echocardiographic feats : -°s of the suspected rejection
episodes included irritability and rest tachycardia in five
episodes, atrial ectopic activity in three episodes, an in-
crease in left ventricular posterior and septal wall thickness
in three episodes (Fig. 1) and ventricular dysfunction with
poor cardiac output in one episode .
Thirty-seven biopsies were performed beginning 6
months after transplantation because of clinical suspicion of
rejection or as a scheduled quarterly procedure . Adequate
biopsy tissue for histologic analysis was obtained in all
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Figure 1. A and B, Two-dimensional parasternal
long-axis echocardiograms from a neonate demon-
strating (A) normal left ventricular posterior wall
thickness (4 mm) and cavity dimensions 2 weeks
after heart transplantation and (B) at 5 weeks after
transplantation demonstrating an acute increase in
left ventricular posterior wall thickness, measuring
8 mm in diameter. C. Same patient. Autopsy speci-
men after sudden death demonstrating dense lym-
phocytic infiltrate with severe myocyte necrosis .
AO = aorta ; LA = left atrium ; LV = left ventricle ;
RV = right ventricle .
cases. Biopsy was performed because of clinically suspected
rejection in eight patients . In five episodes of suspected
rejection manifested by tachycardia and irritability, the
biopsy sample was free of cellular infiltrate . In three pa-
tients, rejection was suspected because of an increase in left
ventricular posterior wall and septal thickness. In these
three cases, the biopsy sampiep demonstrated focal perivas-
cular myocyte damage, interstitial edema and minimal cel-
lular infiltrate (Fig . 1), consistent with vascular/humoral
rejection. In 29 biopsies performed for routine scheduled
quarterly follow-up in asymptomatic patients, the biopsies
were free of evidence of rejection .
Group 11. Thirty episodes of rejection were demon-
strated in 291 biopsies (10%) performed in 18 patients .
Rejection had been clinically suspected in only 7 (23%) of the
30 biopsies demonstrating cellular infiltrate (Fig . 3). Rejec-
tion was clinically suspected on 17 occasions, but only in 7
(41%) of these 17 episodes did the biopsy sample demon-
strate an acute celWar infiltrate. The results of the statistical
analysis of rejection surveillance through clinical and biopsy
methods for Groups I and II are presented in Table 1 .
Safety evaluation. In Group I, the procedures were com-
plicated in 1 (3%) of 37 biopsies, and the patients were
JACC Vol . 23, No . 3
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Figure 2 . Endomyocardial biopsy tissue from a ne-
onate, demonstrating endothelial cell swelling, inter-
stitial myocardial edemaa and minimal lymphocyte
infiltrate.
discharged 6 to 8 h after cardiac catheterizadon and biopsy .
One patient developed a pneumothorav after attempted
intravenous access by the internal jugular approach and
required tube thoracostomy and overnight monitoring .
There were no episodes of new tricuspid regurgitation,
ventricular perfora*ion or hemopericardium detected by
echocardiography. I Group II patients, there were no
complications . Two patients who underwent heart transplan-
tation at age I year are now 3 years posttransplaniation and
have each had >20 biopsies without loss of venous access
from the right femoral vein .
Discussion
Utility of biopsy . This study demonstrates the importance
of endomyocardial biopsy for evaluation of clinically sus-
pected rejection episodes in neonates and for routine rejec-
Figure 3. Endomyocardial biopsy tissue from an
asymptomatic child with no clinical or echocardio-
graphic signs suggesting rejection, demonstrating
grade 3 rejection characterized by dense lympho-
cytic infiltrate with evidence of myocyte damage .
tion surveillance in children after heart transplantation . In
neonates (Group I) with clinically suspected rejection, en-
domyocardial biopsy identified which patients did not re-
quire rejection therapy . In those neonates without clinical
signs of rejection, endomyocar&al biopsy did not identify
any rejection episodes, thus demonstrating that noninvasive
measures alone appear to be sufficient to exclude rejection .
Although noninvasive rejection surveillance assessing heart
rate and echocardiographic left ventricular dimensions and
function was valuable in the initial stages of patient evalua-
tion, these variables could not be relied on for exact diag-
nosis of rejection and institution of therapy . Similar findings
were described by Canter et al . (18), who found that in 10
episodes of clinically suspected rejection, results of all 10
biopsies were negative . However, the number of patients in
both their series and our series was small .
In children (Group 11), noninvasive rejection surveillance
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Bold L Sensitivity of Clinical Suspicion of Rejection With
Respect to Biopsy Findings
Group I (neonates)
Positive Biopsy Negative Biopsy
Result Result (95% Cl)
was less reliable than in neonates . In asymptomatic children,
routine surveillance biopsy detected acute rejection in 8 .4%
of cases. Biopsy confirmed rejection in <5091b of cases of
clinically suspected rejection .
We demonstrated that repeated endomyocardial biopsy is
a safe procedure (with only one complication in >330
procedures) that provides adequate tissue yield for accurate
assessment of cellular rejection and myocyte damage . Bi-
opsy therefore permits the precise documentation of the
presence or absence of rejection, and consequently allows
for titration of immunosuppressive agents to avoid their
known side effects. Similarly, it avoids the risks of infection
associated with excessive pulse steroid therapy if manage-
ment is based on clinical signs alone.
Endomyocardial biopsy also provides tissue for analysis
of humoral (vascular) rejection, as described by Hammond
et al . (19) . In 16 of 36 patients they found humoral rejection
that was associated with significantly decreased survival .
They concluded that immunofluorescence should be rou-
tinely performed on all biopsy specimens during the early
months after transplantation . We found similar histologic
and immunoRtiorescence findings in three neonatal trans-
Plant recipients. Prospective analysis of the relation of
-mmunoglobulin and complement deposits in the coronary
microvasculature may further define the relation of humoral
rejection to accelerated graft coronary artery disease (20) .
EcImKordiographic: surveillance. Various echocardio-
graphic measures for detecting rejection have been studied
in adult patients after heart transplantation. These indexes
are based on the premise that rejection results in abnormal-
ities in diastolic function due to decreased left ventricular
compliance from interstitial edema, cellular infiltrate and
myocyte necrosis. Valantine et al . (21) utilized Doppler
echocardiography to measure isovolumetric relaxation time
and mitral valve pressure half-time after transplantation in 22
patients . They found a progressive decrease in isovolumetric
relaxation time and a decrease in pressure half-time during
biopsy-proved mild (cellular infiltrate) and moderate (myo-
cyte necrosis) episodes of rejection . Desruennes et al. (22)
found a similar decrease in isovolumetric relaxation time and
pressure half-time correlated with rejection on endomyocar-
dial biopsy . After treatment of the rejection episode with
corticosteroids, the Doppler flow indexes returned to base-
line values . However, in a subsequent study by Valantine et
al . (23), recipient atrial contraction during systole was found
to also shorten isovolumetric relaxation time and pressure
half-time. This variation in timing of recipient atrial activity
and the faster heart rates at rest in young children make
these noninvasive Doppler studies less reliable and we (24)
have not found them to be helpful .
Other surveillance methods. Cytoimmunologic monitor-
ing of lymphocyte activation during cardiac allograft rejec-
tion has been reintroduced with the application of flow
cytometry and monoclonal antibody markers . In previous
studies by Fieguth et al . (25) in which lymphoblasts and
prelymphoblasts were characterized, the overall sensitivity
was 7(% and specificity 79% compared with endomyocardial
biopsy. This method became less useful as time progressed
after transplantation. Analysis of these techniques during
infectious episodes revealed activation of lymphocytes no
different from that seen in rejection episodes . They con-
cluded that cytoimmunologic monitoring is a useful adjunct
to the biopsy procedure but that it could not replace routine
surveillance biopsies .
Newer noninvasive surveillance modalities include tissue
characterization of the myocardium by echocardiography
and radionuclidc indium-II I antimyosin imaging . Prelimi-
nary animal and human studies suggest that these new
techniques (26-28) provide identification of severe -ejection
episodes associated with myocyte damage but are less
reliable in mild or moderate episodes .
Conclusions. On the basis of our experience in neonatal
transplant recipients with clinically suspected rejection, en-
domyocardial biopsy identified which patients did nw re-
quire rejection therapy . Noninvasive measures alone appear
to provide sufficient rejection surveillance in neonates with-
nut clinical signs of rejection. In children, noninvasive
rejection surveillance was less reliable even in asymptomatic
patients, suggesting that endomyocardial biopsy should be
utilized . Endomyocardial biopsy is a low risk procedure that
provides an accurate determination of rejection, and there-
fore appropriately guides immunosuppressive therapy after
heart transplantation .
Clinically suspected (no.)
Periodic surveillance (no .)
Proportion of rejection episodes
detected by periodic surveillance
Proportion of periodic surveillance
"identifying" rejection
Proportion of clinically suspected
rejection confirmed by biopsy
Proportion of procedures with
complication
3
0
0%
0%
38%
3%
5
29
0%-63%
0%-12%
16%-75%
0%-12%
Group 11 (children)
Clinically suspected (no.) 7 10
Periodic surveillance (no .) 23 251
Proportion of rejection episodes 77% 617v.-91%
detected by periodic surveillance
Proportion of periodic surveillance 8% 5%-12%
,, identifying" rejection
Proportion of clinically suspected 41% 2317o-67%
rejection confirmed by biopsy
Proportion of procedures with 0% < 1 .8%
complication
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